Clinical Development

Q3 revenues dip for Pharsight

Q3 revenues dip for Pharsight

By Kirsty Barnes

Pharsight, a provider of software and strategic services for
clinical drug development, has seen its revenues dip for the second
quarter in a row due to lower-than-expected business from a top
client in its strategic consulting services...

Phase IIIB-IV research booming

Outsourcing-Pharma: Focus on Phase IIIB-IV research

Phase IIIB-IV research booming

By Kirsty Barnes

Phase IIIB-IV clinical research in the US is now booming, growing
20 per cent annually, compared with only 7 per cent for Phase
II-III research, driven by a surge in public drug safety concerns
and increased drug market competitiveness.

Covance ends 2005 on the upswing

Covance ends 2005 on the upswing

By Kirsty Barnes

Covance closed 2005 on a high after net revenues climbed 16.9 per
cent from 2004 to reach $1.19 bn (€1 bn). The current trend towards
outsourcing R&D, coupled with increased productivity and repeat
business has fuelled the company's...

Ventiv partners with Indian CRO

Ventiv partners with Indian CRO

By Kirsty Barnes

Ventiv's Clinical Services division has joined with India's largest
domestic contract research organization (CRO), SIRO Clinpharm, to
provide India-based clinical data management services, offering
pharma and biotech companies...

Ventiv in good health

Ventiv in good health

By Kirsty Barnes

Ventiv health reported a strong performance across all its business
units in the third quarter, with total revenues increasing by 44
per cent to $128.4 million (€107.6 million) compared to the third
quarter of 2004.

UK boost to biomanufacturing

UK boost to biomanufacturing

By Kirsty Barnes

SR Pharma, specializing in RNAi therapeutics, will be the first
company to use the new UK National Biomanufacturing Centre (NBC),
operated by contract manufacturing organization (CMO) Eden
Biodesign, when it opens on schedule early...

Western CROs get proactive

Western CROs get proactive

By Kirsty Barnes

Contract research organisations (CROs) are responding to the
looming threat of competition from India and China by moving
outside their traditional role of simply providing contract
services to drug companies.

Covalent improves 3Q finances

Covalent improves 3Q finances

By Kirsty Barnes

Covalent Group has improved its financial position on last year,
reporting a net revenue increase of 45 per cent for the third
quarter of 2005 with sales of $2.7 million, (€2.3 million) compared
to $1.9 million one year ago.

Accelovance advance in China

Accelovance advance in China

By Kirsty Barnes

Accelovance has broadened its presence in China and expanded its
capacity for conducting Phase I-IV clinical trials for Western
pharmaceutical and biotech firms seeking to enter the Chinese
market, by opening a new office in Shanghai.